This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)

This study has been completed.
Immune Tolerance Network (ITN)
Information provided by:
Neurocrine Biosciences Identifier:
First received: March 8, 2004
Last updated: March 20, 2008
Last verified: September 2007

We are studying this investigational drug treatment, comparing it with placebo, to evaluate whether it is effective in reducing the number of MRI lesions with a minimum number of side effects. The investigational drug will be administered in the clinic weekly for 5 injections (induction phase) then monthly for 8 additional injections (maintenance phase).

Approximately 150 male and female patients (100 active and 50 placebo), aged 18 to 55 years, with relapsing MS and at least one but no more than 10 total Gd-enhancing lesions on cranial MRI scans during the run-in phase will be randomized into this study.

Condition Intervention Phase
Multiple Sclerosis Drug: NBI-5788 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by Neurocrine Biosciences:

Estimated Enrollment: 150
Study Start Date: July 2003
Estimated Study Completion Date: April 2005
Detailed Description:
This is a multicenter, randomized, double-blind, placebo-controlled trial in which qualifying patients will be randomized 2:1 to receive active drug or placebo. Eligible patients must have MS with relapse, have had one or more relapses during the prior 2 years, 1-10 gadolinium (Gd)-enhancing lesions on the Run-in MRI, and an EDSS of 6.5 or less. There are exclusions for certain prior MS treatments and medical / psychiatric conditions. Following a 4-week run-in phase in which patients will have a baseline MRI, patients will enter a 4 week induction phase, during which they will be receive injections weekly (5 doses), then a 32-week maintenance phase during which injections are monthly (8 doses). A final follow-up visit will be conducted 4 weeks after the last injection. The primary efficacy parameter is a summary change score of the mean number of total Gd-enhancing lesions at weeks 36 and 40 minus the mean number for the two baseline scans. Safety monitoring will include AE/SAE reporting, physical exams, vital signs, ECG. CXR, laboratory tests, neurologic evaluations, and systemic hypersensitivity and injection site assessments. All study medications will be administered by study personnel and patients will remain under observation for a minimum of 2 hours post-injection. An independent Data Safety and Monitoring Board will oversee the safety of the trial.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female, 18 to 55 years of age
  • Diagnosed with relapsing multiple sclerosis, with at least one relapse in the last two years
  • Females must not plan on becoming pregnant
  • Females must either be post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control and willing to continue birth control until 30 days after the last dose of study drug
  • Males must not intend to impregnate a partner during the study or for 30 days after the study and must also practice acceptable birth control with their partners

Exclusion Criteria:

  • Significant long-lasting disease of the immune system other than multiple sclerosis
  • Past or current medical disease (heart, liver, kidney, etc.) including severe asthma, cancer or advancing brain or spinal cord disorder
  • Known or suspected long-lasting infectious disease including HIV, hepatitis B, or hepatitis C
  • Treatment with certain steroid or hormone medications within 30 days before the pre-study MRI scan
  • Treatment with other medications that suppress the immune system within 6 months before the pre-study MRI scan
  • Certain treatments and medications are not allowed
  • Laboratory and other tests will be performed to determine further eligibility
  • History of drug or alcohol abuse in the last year
  • History of medical or psychiatric condition that could pose a risk for participation in the study
  • Females who are pregnant or breast feeding
  • Participation in any other trial of an investigational agent within 90 days before the start of the study
  • History of not following instructions with past therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00079495

Sponsors and Collaborators
Neurocrine Biosciences
Immune Tolerance Network (ITN)
Study Director: Chris O'Brien, MD Neurocrine Biosciences
  More Information

Additional Information: Identifier: NCT00079495     History of Changes
Other Study ID Numbers: NBI-5788-0201
Study First Received: March 8, 2004
Last Updated: March 20, 2008

Keywords provided by Neurocrine Biosciences:
Autoimmune disease
Myelin Basic Protein
acute fulminating
chronic progressive
Altered Peptide Ligand

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases processed this record on July 27, 2017